newsfilter
← Latest News
GlobeNewswire·

Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026Initial data from